PhRMA Donut Hole Pledge Sets Nice Tone, But Negotiations Continue On $80 Bil. Contribution
This article was originally published in The Pink Sheet Daily
Executive Summary
Higher drug rebates to Medicaid, Medicare under discussion, as are savings from follow-on biologics.
You may also be interested in...
Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill
The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole
Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill
The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole
Getting To $80 Bil.: PhRMA Expects Mix Of Drug Rebates And Fees In Senate Finance Bill
In addition to the announced discount for drugs in the Part D donut hole, PhRMA anticipates the Senate Finance Committee's bipartisan bill will seek rebates and fees from pharmaceutical manufacturers.